[1] Satapathy SK, Sanyal AJ.Epidemiology and natural history of nonalcoholic fatty liver disease[J]. Semin Liver Dis,2015,35(3):221-235.
[2] Angulo P, Lindor KD. Non-alcoholic fatty liver disease[J]. J Gastroenterol Hepatol,2002,17 Suppl:S186-S190.
[3] Wu R, Hou F, Wang X, et al.Nonalcoholic fatty liver disease and coronary artery calcification in a northern Chinese population: a cross sectional study[J]. Sci Rep,2017,7(1):9933.
[4] Copple BL, Li T.Pharmacology of bile acid receptors: evolution of bile acids from simple detergents to complex signaling molecules[J]. Pharmacol Res,2016,104:9-21.
[5] Song P, Rockwell CE, Cui JY, et al.Individual bile acids have differential effects on bile acid signaling in mice[J]. Toxicol Appl Pharmacol,2015,283(1):57-64.
[6] Wang C, Yang C, Chang JY, et al.Hepatocyte FRS2alpha is essential for the endocrine fibroblast growth factor to limit the amplitude of bile acid production induced by prandial activity[J]. Curr Mol Med,2014,14(6):703-711.
[7] Deutschmann K, Reich M, Klindt C, et al.Bile acid receptors in the biliary tree: TGR5 in physiology and di-sease[J]. Biochim Biophys Acta,2018,1864(4 Pt B):1319-1325.
[8] Arab JP, Karpen SJ, Dawson PA, et al.Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives[J]. Hepatology,2017,65(1):350-362.
[9] Schaap FG, Trauner M, Jansen PL.Bile acid receptors as targets for drug development[J]. Nat Rev Gastroenterol Hepatol,2014,11(1):55-67.
[10] Mazuy C, Helleboid A, Staels B, et al.Nuclear bile acid signaling through the farnesoid X receptor[J]. Cell Mol Life Sci,2015,72(9):1631-1650.
[11] Carr RM, Reid AE.FXR agonists as therapeutic agents for non-alcoholic fatty liver disease[J]. Curr Atheroscler Rep,2015,17(4):500.
[12] Fuchs CD, Traussnigg SA, Trauner M.Nuclear receptor modulation for the treatment of nonalcoholic fatty liver disease[J]. Semin Liver Dis,2016,36(1):69-86.
[13] Cariou B, Chetiveaux M, Zair Y, et al.Fasting plasma chenodeoxycholic acid and cholic acid concentrations are inversely correlated with insulin sensitivity in adults[J]. Nutr Metab (Lond),2011,8(1):48.
[14] Jahn D, Rau M, Hermanns HM, et al.Mechanisms of enterohepatic fibroblast growth factor 15/19 signaling in health and disease[J]. Cytokine Growth Factor Rev,2015, 26(6):625-635.
[15] Pols TW, Noriega LG, Nomura M, et al.The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation[J]. J Hepatol,2011,54(6):1263-1272.
[16] Broeders EP, Nascimento EB, Havekes B, et al.The bile acid chenodeoxycholic acid increases human brown adipose tissue activity[J]. Cell Metab,2015,22(3):418-426.
[17] Perino A, Schoonjans K.TGR5 and immunometabolism: insights from physiology and pharmacology[J]. Trends Pharmacol Sci,2015,36(12):847-857.
[18] Boursier J, Mueller O, Barret M, et al.The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota[J]. Hepatology,2016,63(3):764-775.
[19] Ridlon JM, Bajaj JS.The human gut sterolbiome: bile acid-microbiome endocrine aspects and therapeutics[J]. Acta Pharm Sin B,2015,5(2):99-105.
[20] Kohli R, Myronovych A, Tan BK, et al.Bile acid signa-ling: Mechanism for bariatric surgery, cure for NASH?[J]. Dig Dis,2015,33(3):440-446.
[21] Fang S, Suh JM, Reilly SM, et al.Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance[J]. Nat Med,2015,21(2):159-165.
[22] Parseus A, Sommer N, Sommer F, et al.Microbiota-induced obesity requires farnesoid X receptor[J]. Gut,2017, 66(3):429-437.
[23] Ali AH, Carey EJ, Lindor KD.Recent advances in the development of farnesoid X receptor agonists[J]. Ann Transl Med,2015,3(1):5.
[24] Liu X, Xue R, Ji L, et al.Activation of farnesoid X receptor(FXR) protects against fructose-induced liver steatosis via inflammatory inhibition and ADRP reduction[J]. Biochem Biophys Res Commun,2014,450(1):117-123.
[25] Fickert P, Fuchsbichler A, Moustafa T, et al.Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts[J]. Am J Pathol,2009,175(6):2392-2405.
[26] Mudaliar S, Henry RR, Sanyal AJ, et al.Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease[J]. Gastroenterology,2013,145(3):574-582,e571.
[27] Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al.Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial[J]. Lancet,2015,385(9972):956-965.
[28] Jiang C, Xie C, Lv Y, et al.Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction[J]. Nat Commun,2015,6:10166.
[29] Prawitt J, Abdelkarim M, Stroeve JH, et al.Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity[J]. Diabetes,2011,60(7):1861-1871.
[30] McMahan RH, Wang XX, Cheng LL, et al. Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease[J]. J Biol Chem,2013,288(17):11761-11770.
[31] Armstrong MJ, Gaunt P, Aithal GP, et al.Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study[J]. Lancet,2016,387(10019):679-690.
[32] Ferrebee CB, Dawson PA.Metabolic effects of intestinal absorption and enterohepatic cycling of bile acids[J]. Acta Pharm Sin B,2015,5(2):129-134.
[33] Gawrieh S, Chalasani N.Pharmacotherapy for nonalcoholic fatty liver disease[J]. Semin Liver Dis,2015,35(3):338-348.
[34] Leuschner UF, Lindenthal B, Herrmann G, et al.High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial[J]. Hepatology,2010,52(2):472-479.
[35] Beraza N, Ofner-Ziegenfuss L, Ehedego H, et al.Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis[J]. Gut,2011,60(3):387-396.
[36] Safadi R, Konikoff FM, Mahamid M, et al.The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease[J]. Clin Gastroenterol Hepatol,2014,12(12):2085-2091. |
